Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation.
Ocio EM, Perrot A, Bories P, San-Miguel JF, Blau IW, Karlin L, Martinez-Lopez J, Wang SY, Bringhen S, Marcatti M, Mateos MV, Rodriguez-Otero P, Oliva S, Nogai A, Le Roux N, Dong L, Macé S, Gassiot M, Fitzmaurice T, Oprea C, Moreau P. Ocio EM, et al. Leukemia. 2023 Jul;37(7):1521-1529. doi: 10.1038/s41375-023-01936-7. Epub 2023 Jun 14. Leukemia. 2023. PMID: 37316728 Free PMC article. Clinical Trial.
Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody.
Raab MS, Cohen YC, Schjesvold F, Aardalen K, Oka A, Spencer A, Wermke M, Souza AD, Kaufman JL, Cafro AM, Ocio EM, Doki N, Henson K, Trabucco G, Carrion A, Bender FC, Juif PE, Fessehatsion A, Fan L, Stonehouse JP, Blankenship JW, Granda B, De Vita S, Lu H. Raab MS, et al. Among authors: ocio em. Leukemia. 2023 Jun;37(6):1349-1360. doi: 10.1038/s41375-023-01883-3. Epub 2023 Apr 6. Leukemia. 2023. PMID: 37024520
Feasibility of a Hospital-at-Home Program for Autologous Hematopoietic Stem Cell Transplantation.
González-Barrera S, Martín-Sánchez G, Parra-Jordán JJ, Fernández-Luis S, Calvo JA, Lobeira R, Yañez L, Manzano A, Carrera C, Baro J, Richard C, Bermúdez A, Ocio EM, Sanroma P. González-Barrera S, et al. Among authors: ocio em. Transplant Cell Ther. 2023 Feb;29(2):111.e1-111.e7. doi: 10.1016/j.jtct.2022.11.018. Epub 2022 Nov 24. Transplant Cell Ther. 2023. PMID: 36436783 Free article.
Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study.
Ocio EM, Montes-Gaisán C, Bustamante G, Garzón S, González E, Pérez-Persona E, González-Calle V, Sirvent M, Arguiñano JM, González Y, Ríos R, de Miguel D, Grande M, Fernández-Nistal A, Naves A, Rosiñol L. Ocio EM, et al. Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):e341-e347. doi: 10.1016/j.clml.2023.07.006. Epub 2023 Jul 15. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37517875 Free article.
Feasibility of allogeneic hematopoietic stem cell transplantation in advanced age.
Fernandez-Luis S, Gomez Lamas D, Cerezo Martin JM, Mora Barrios JM, Yañez San Segundo L, Sanchez Escamilla M, Fernandez-Escalada N, Calvo Sanchez JA, Fernandez Garcia S, Dominguez-Garcia JJ, Colorado Araujo M, Lopez-Duarte M, Martin-Sanchez G, Insunza Gaminde A, Romon Alonso JI, Lobeira Rubio R, Arroyo Rodriguez JL, Rueda Ciller B, Hermosilla Fernandez M, Marco Betes V, Ocio EM, Bermudez Rodriguez A. Fernandez-Luis S, et al. Among authors: ocio em. Ann Hematol. 2024 Feb;103(2):583-591. doi: 10.1007/s00277-023-05521-x. Epub 2023 Nov 4. Ann Hematol. 2024. PMID: 37923805
Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands.
Díaz-Tejedor A, Rodríguez-Ubreva J, Ciudad L, Lorenzo-Mohamed M, González-Rodríguez M, Castellanos B, Sotolongo-Ravelo J, San-Segundo L, Corchete LA, González-Méndez L, Martín-Sánchez M, Mateos MV, Ocio EM, Garayoa M, Paíno T. Díaz-Tejedor A, et al. Among authors: ocio em. Int J Mol Sci. 2024 Apr 26;25(9):4718. doi: 10.3390/ijms25094718. Int J Mol Sci. 2024. PMID: 38731936
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.
Medina-Herrera A, Vazquez I, Cuenca I, Rosa-Rosa JM, Ariceta B, Jimenez C, Fernandez-Mercado M, Larrayoz MJ, Gutierrez NC, Fernandez-Guijarro M, Gonzalez-Calle V, Rodriguez-Otero P, Oriol A, Rosiñol L, Alegre A, Escalante F, De La Rubia J, Teruel AI, De Arriba F, Hernandez MT, Lopez-Jimenez J, Ocio EM, Puig N, Paiva B, Lahuerta JJ, Bladé J, San Miguel JF, Mateos MV, Martinez-Lopez J, Calasanz MJ, Garcia-Sanz R; GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group. Medina-Herrera A, et al. Among authors: ocio em. Blood Cancer J. 2024 Apr 29;14(1):74. doi: 10.1038/s41408-024-01053-3. Blood Cancer J. 2024. PMID: 38684670 Free PMC article. Clinical Trial.
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.
Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk NWCJ, Ocio EM, Martinez-Lopez J, Rodríguez-Otero P, Dytfeld D, Diels J, Strulev V, Haddad I, Renaud T, Ammann E, Cabrieto J, Perualila N, Gan R, Zhang Y, Parekh T, Albrecht C, Weisel K, Mateos MV. Einsele H, et al. Among authors: ocio em. Adv Ther. 2024 Apr;41(4):1576-1593. doi: 10.1007/s12325-024-02797-x. Epub 2024 Feb 24. Adv Ther. 2024. PMID: 38402374 Free PMC article.
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.
Ocio EM, Efebera YA, Hájek R, Straub J, Maisnar V, Eveillard JR, Karlin L, Mateos MV, Oriol A, Ribrag V, Richardson PG, Norin S, Obermüller J, Bakker NA, Pour L. Ocio EM, et al. Haematologica. 2024 Mar 1;109(3):867-876. doi: 10.3324/haematol.2023.283490. Haematologica. 2024. PMID: 37646657 Free PMC article. Clinical Trial.
138 results